The ASCO 2026 presentation of HARMONi-6 OS data on May 31 is the next major catalyst. The HARMONi-3 squamous interim PFS analysis did not stop early, but the final PFS readout in H2 2026 remains a key event. The PDUFA date in November 2026 provides a longer-term binary catalyst. Monitor cash burn trajectory given $598.7M in cash.
SMMT drugs
SMMT drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 1 $16.12entry
- T+1 · 7mo ago +5.37%α +5.71% · $16.98
- T+5 · 7mo ago +6.42%α +4.08% · $17.15
- T+20 · 6mo ago −2.51%α −7.80% · $15.71
- T+60 · 4mo ago −22.12%α −25.19% · $12.55
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Summit Therapeutics reported Q1 2026 financial results and operational progress. The company posted a GAAP net loss of $189.4M ($0.24/share), wider than the $62.9M loss in Q1 2025, driven by increased R&D and stock-based compensation. Key catalysts include the upcoming ASCO 2026 presentation of HARMONi-6 overall survival data as a late-breaking abstract and the HARMONi-3 squamous cohort final PFS data expected in H2 2026, with the PDUFA date for ivonescimab BLA set for November 14, 2026.
Key Financial Metrics
Key Facts
- GAAP net loss of $189.4M ($0.24/share) in Q1 2026 vs $62.9M ($0.09/share) in Q1 2025
- Cash and short-term investments at $598.7M as of March 31, 2026, down from $713.4M at year-end 2025
- HARMONi-6 overall survival data selected as late-breaking abstract for ASCO 2026 Plenary Session on May 31, 2026
- HARMONi-3 squamous cohort interim PFS analysis completed; iDMC recommended study continue; final PFS data expected H2 2026
- FDA PDUFA goal date for ivonescimab BLA is November 14, 2026
- Non-GAAP net loss was $116.6M ($0.15/share) in Q1 2026 vs $51.8M ($0.07/share) in Q1 2025
Financial Impact
No revenue reported; operating cash burn of $122.3M in Q1 2026 vs $61.1M in Q1 2025
Risk Factors
- Clinical trial failure risk for ivonescimab in ongoing Phase III studies
- Cash burn rate increasing; $598.7M may not be sufficient to fund all planned trials to completion
- Regulatory risk: FDA may not approve ivonescimab by PDUFA date or may require additional data
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001599298-26-000037 |
| Document: smmt-20260430.htm | 0001599298-26-000037 |
| Document: 0001599298-26-000037-index-headers.html | 0001599298-26-000037 |
| Document: 0001599298-26-000037-index.html | 0001599298-26-000037 |
| Document: 0001599298-26-000037.txt | 0001599298-26-000037 |
| 8-K Data (Synthetic) | 0001599298-26-000037 |
Track record
24 reports on SMMT
8 of 13 bullish or bearish reports moved the stock their way by T+1. Best: +23.34% at T+60 after the Jun 12, 2026 report. 10 of 13 went positive at some point.
Filters
- Nov 18, 20263d ago 8-K Neutral 4/10 Entry $10.50 to $10.57 Now $9.95 −5.24% ▲ +0.67% +2.63% vs SPY
- Nov 16, 20266d ago 8-K Bearish 7/10 Entry $11.82 to $10.67 Now $9.95 +15.82% ▲ +9.73% +8.71% vs SPY
- Nov 4, 202617d ago 8-K Neutral 3/10 Entry $14.19 to $16.33 Now $9.95 −29.88% ▲ +15.08% +14.77% vs SPY
- Nov 4, 202617d ago 8-K Neutral 6/10 Entry $14.19 to $16.33 Now $9.95 −29.88% ▲ +15.08% +14.77% vs SPY
- Nov 4, 202617d ago Institutional Cluster Neutral 3/10 Entry $16.17 to $14.19 Now $9.95 −38.47% ▼ −12.24% −7.84% vs SPY
- Oct 21, 20264w ago Press Release Neutral 5/10 Entry $15.83 to $15.55 Now $9.95 −37.14% ▼ −1.77% −0.59% vs SPY
- Oct 19, 20264w ago DEF 14A Neutral 5/10 Entry $15.57 to $16.09 Now $9.95 −36.10% ▲ +3.34% +3.00% vs SPY
- Sep 28, 20267w ago 8-K Bullish 8/10 Entry $16.39 to $16.91 Now $9.95 −39.29% ▲ +3.17% +3.38% vs SPY
- Sep 15, 20269w ago 8-K Bullish 7/10 Entry $17.40 to $17.54 Now $9.95 −42.82% ▲ +0.80% +0.48% vs SPY
- Sep 14, 20269w ago 8-K Bullish 7/10 Entry $18.42 to $17.40 Now $9.95 −45.98% ▼ −5.54% −5.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers